SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review

被引：6

作者：

Xu, Rong ^{[1
,2
]}

Lian, Difei ^{[1
,2
]}

Xie, Yan ^{[1
,2
]}

Chen, Zhilei ^{[1
,2
]}

Wang, Yan ^{[1
,2
]}

Mu, Lin ^{[1
,2
]}

Wang, Yuan ^{[1
,2
]}

Zhang, Baoyu ^{[1
,2
]}

机构：

[1] Capital Med Univ, Lu He Hosp, Ctr Endocrine Metab & Immune Dis, Beijing 100000, Peoples R China

[2] Beijing Key Lab Diabet Res & Care, Beijing 100000, Peoples R China

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2023年 / 28卷 / 07期

关键词：

SGLT-2; inhibitors; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; type; 2; diabetes; TYPE-2; DIABETES-MELLITUS; PPAR-ALPHA/GAMMA AGONIST; GLP-1 RECEPTOR AGONISTS; INSULIN-CLEARANCE; DOUBLE-BLIND; INFLAMMASOME ACTIVATION; HEPATIC STEATOSIS; BARIATRIC SURGERY; OBETICHOLIC ACID; REDUCES FEATURES;

D O I：

10.31083/j.fbl2807134

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Non-alcoholic fatty liver disease (NAFLD) is a group of metabolic liver illnesses that lead to accumulation of liver fat mainly due to excessive nutrition. It is closely related to insulin resistance, obesity, type 2 diabetes, and cardiovascular disease, and has become one of the main causes of chronic liver disease worldwide. At present, there is no specific drug for the treatment of NAFLD; lifestyle interventions including dietary control and exercise are recommended as routine treatments. As a drug for the treatment of type 2 diabetes, sodium-glucose co-transporter type 2 (SGLT-2) inhibitors may also play a beneficial role in the treatment of NAFLD. This article reviews the mechanism of SGLT-2 inhibitors in the treatment of NAFLD.

引用

页数：12

共 50 条

[1] ASSESSING THE ROLE OF SGLT-2 INHIBITORS WITH DIABETES AND NON-ALCOHOLIC FATTY LIVER DISEASE-A SYSTEMATIC REVIEW
Agrawal, Rohit
Ghoulam, Elie
Chan, Christine
GASTROENTEROLOGY, 2021, 160 (06) : S842 - S842
[2] SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
Raj, Henith
Durgia, Harsh
Palui, Rajan
Kamalanathan, Sadishkumar
Selvarajan, Sandhiya
Kar, Sitanshu Sekhar
Sahoo, Jayaprakash
WORLD JOURNAL OF DIABETES, 2019, 10 (02) : 114 - 132
[3] The Effect of SGLT-2 Inhibitors on Improving Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Sayeh, Wasef
Dhoop, Sudheer
Chinnam, Sahithi
Musallam, Rami
Patel, Rayna
Beran, Azizullah
Karrick, Megan
Renno, Anas
Nawras, Ali
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S1022 - S1022
[4] SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
Gharaibeh, Naser Eddin
Rahhal, Marie-Noel
Rahimi, Leili
Ismail-Beigi, Faramarz
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 1001 - 1012
[5] Non-alcoholic Fatty Liver Disease: Better Results with SGLT2 Inhibitors
Simon, Annika
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2024, 62 (09): : 1360 - 1361
[6] Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review
Kaur, Simran
Sojitra, Vani
Zahra, Anam
Hutchinson, Jhenelle
Folawemi, Oluwa
Bittla, Parikshit
Ramphall, Shivana
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
[7] SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease
Mirarchi, Luigi
Amodeo, Simona
Citarrella, Roberto
Licata, Anna
Soresi, Maurizio
Giannitrapani, Lydia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
[8] Non-alcoholic fatty liver disease: A brief review
van Hoek, B
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2004, 39 : 56 - 59
[9] A Comprehensive Review on Non-Alcoholic Fatty Liver Disease
Sahu, Prerna
Chhabra, Pratyaksh
Mehendale, Ashok M.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
[10] Non-alcoholic fatty liver disease:An expanded review
Mark Benedict
Xuchen Zhang
World Journal of Hepatology, 2017, (16) : 715 - 732

← 1 2 3 4 5 →